Juvenile idiopatic arthritis associated uveitis
Authors:
H. Malcová 1; T. Dallos 2; R. Horváth 1; P. Doležalová 3; M. Macků 4; D. Němcová 3; E. Říhová 5; P. Svozílková 5; M. Brichová 5; B. Kostolná 6; prof. MUDr. Jarmila Heissigerová, Ph.D., MBA 5
Authors‘ workplace:
Oddělení revmatologie dětí a dospělých, Fakultní nemocnice Motol, Praha
1; Detská klinika Lekárskej fakulty Univerzity Komenského a Národného ústavu detských chorôb,
Bratislava
2; Centrum dětské revmatologie a autoinflamatorních onemocnění, Klinika dětského a dorostového
lékařství 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha
3; Pediatrická klinika, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno
4; Oční klinika 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha
5; Klinika detskej oftalmológie Lekárskej fakulty Univerzity Komenského a Národného ústavu
detských chorôb, Bratislava
6
Published in:
Čes-slov Pediat 2018; 73 (4): 189-197.
Category:
Overview
Chronic anterior uveitis is the most common extraarticular manifestation of juvenile idiopathic arthritis (JIA). It is a serious eye disease, potentially threatening the patient with irreversible visual damage to vision loss. Exact pathogenetic mechanism leading to the intraocular inflammation development is not known, but it is likely to be an interaction of the individual's genetic disposition and external environmental factors. The most common manifestation is chronic anterior uveitis, usually asymptomatic, therefore systematic screening and long-term follow-up of patients at risk is absolutely fundamental.
Recently, the spectrum of therapeutic possibilities for JIA associated uveitis is expanding. In addition to topical treatment, systemic corticosteroids and conventional synthetic disease modifying antirheumatic drugs (csDMARDs), also biological drugs (bDMARDs) are increasingly used.
The objective of this article is to provide an up-to-date overview of this area and recent information on the recommendations for diagnosis and treatment of JIA-associated chronic uveitis.
Key words:
JIA, uveitis, screening, treatment
Sources
1. Holland GN, Stiehm ER. Special considerations in the evaluation and management of uveitis in children. J Ophthalmology 2003; 135: 867–878.
2. Cuningham ET Jr. Uveitis in children. Ocul Immunol Inflamm 2000; 8: 251–261.
3. Heiligenhaus A, Heinz C, Edelsten C, et al. Review of disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 2013; 21: 180–191.
4. Tugal-Tutkun I, Havrlikova K, Power WJ, Foster CS. Changing patterns of uveitis of childhood. Ophthalmology 1996; 103: 375–383.
5. Oray M, Tugal-Tutkun I. Treatment of juvenile idiopathic arthritis-associated uveitis. Turk J Ophtalmol 2016; 46: 77–82.
6. Hoeve M, Kalinina Ayuso V, Schalij-Delfos NE, et al. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty. Br J Ophthalmol 2012; 96 (6): 852–856.
7. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 2003; 135 (5): 676–680.
8. de Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87 (7): 879–884.
9. BenEzra D, Cohen E, Maftzir G. Uveitis in children and adolescents. Br J Ophthalmol 2005; 89 (4): 444–448.
10. Kump LI, Cervantes-Castañeda RA, Androudi SN, Foster CS. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology 2005; 112 (7): 1287–1292.
11. Tappeiner C, Klotsche J, Schenck S, et al. Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis:data from a cross-sectional analysis of a prospective nationwide study. Clin Exp Rheumatol 2015; 33 (6): 936–944.
12. Tappeiner C, Schenck S, Niewerth M, et al. Impact of anti-inflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: Longitudinal analysis from a nation-wide paediatric rheumatological database. Arthritis Care Res 2016; 68 (1): 46–54.
13. Heiligenhaus A, Minden K, Foll D, et al. Uveitis in juvenile idiopathic arthritis. Dtsch Arztebl Int 2015; 112: 92–100.
14. Angeles-Han ST, Pelajo CF, Vogler LB, et al. Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 2013; 40 (12): 2088–2096.
15. Moradi A, Amin RM, Thorne JE. The role of gender in juvenile idiopathic arthritis-associated uveitis. J Ophthalmol 2014; 2014: 461078.
16. Saurenmann RK, Rose JB, Tyrrell P, et al. Epidemiology of juvenile idio-pathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 2007; 56 (6): 1974–1984.
17. Julián K, Terrada C, Quartier P, et al. Uveitis related to juvenile idiopathic arthritis: familial cases and possible genetic implication in the pathogenesis. Ocul Immunol Inflamm 2010; 18 (3): 172–177.
18. Heiligenhaus AI, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46: 1015–1019.
19. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol 2015; 11 (6): 338–348.
20. Tappeiner C, Heinz C, Roesel M, Heiligenhaus A. Elevated laser flare values correlate with complicated course of anterior uveitis in patients with juvenile idiopathic arthritis. Acta Ophthalmol 2011; 89 (6): 521–527.
21. Deschenes J, Murray PI, Rao NA, Nussenblatt RB, International Uveitis Study Group. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm 2008; 16 (1): 1–2.
22. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140 (3): 509–516.
23. British Society for Paediatric and Adolescent Rheumatology, Royal College of Ophthalmology. Guidelines for Screening for Uveitis in Juvenile Idiopathic Arthritis. 2006.
24. Bou R, Adan A, Borras F, et al. Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int 2015; 35 (5): 777–785.
25. Heinz C, Schumacher C, Roesel M, Heiligenhaus A. Elevated intraocular pressure in uveitis associated with juvenile idiopathic arthritis-associated uveitis, often detected after achieving inactivity. Br J Ophthalmol 2012; 96 (1): 140–141.
26. Heiligenhaus A, Michels H, Schumacher C, et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 2012; 32 (5): 1121–1133.
27. Clarke SLN, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol 2016; 14: 27.
28. Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117 (7): 1436–1441.
29. Heiligenhaus A, Tappeiner C, Walscheid K, et al. Uveitis associated with juvenile idiopathic arthritis: optimization of immunomodulatory therapy. Ophtalmologe 2016; 113: 391–397.
30. Charkoudian LD, Ying GS, Pujari SS, et al. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm 2012; 20 (2): 91–99.
31. Ramanan AV, Dick AD. Blinded by lack of evidence. Rheumatology 2013; 52 (5):765–766.
32. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side- effects of injection of posterior sub-tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophtalmol 2004; 32: 563–568.
33. The Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis: The multicenter uveitis steroid treatment trial. Ophthalmology 2011; 118 (10): 1916–1926.
34. Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology 2013; 52 (5): 825–831.
35. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32 (2): 362–365.
36. Foeldvari I, Becker I, Horneff G. Uveitis events during Adalimumab, Etnercept, and Methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in pediatric rheumatology registry. Arthritis Care Res 2015; 67: 1529–1535.
37. Van Dijkhuizen EH, Pouw JN, Scheuern A, et al. Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study. Clin Exp Rheumatol 2016; 34: 148–154.
38. Sijssens KM, Rothova A, Van De Vijver DA, et al. Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2007; 144 (4): 574–579.
39. Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151 (2): 217–222.
40. Amarilyo G, Rullo OJ, Mccurdy DK, et al. Folate usage in MTX-treated juvenile iiopathic arthritis (JIA) patients is inconsistent and highly variable. Rheumatology Int 2013; 33: 2437–2440.
41. Falvey S, Shipman L, Ilowite N, Beukelman T. Methotrexate-induced nauzea in the treatment of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2017; 15: 52.
42. Bichler J, Benseler SM, Krumrey-Langkammerer M, et al. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Scand J Rheumatol 2015; 44 (4): 280–283.
43. Little JA, Sen ES, Strike H, et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. J Rheumatol 2014; 41 (1): 136–139.
44. Tynjälä P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66 (4): 548–550.
45. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology 2005; 44 (8): 1008–1011.
46. Saurenmann RK, Levin AV, Feldman BM, et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006; 149 (6): 833–836.
47. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56 (10): 3248–3252.
48. Verazza S, Davi S, Consolaro A, et al. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatr Rheumatol Online J 2016; 14: 68.
49. Simonini G, Druce K, Cimaz R, et al. Current evidence of anti-tumor necrosis factor – treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res 2014; 66 (7): 1073–1084.
50. Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017; 376: 1637–1646.
51. Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013; 40: 74–79.
52. Felis-Giemza A, Moots RJ. Measurement of anti-drug antibodies to biologic drugs. Rheumatology (Oxford) 2015; 54: 1941–1943.
53. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in dose dependent manner. Ann Rheum Dis 2012; 71: 1914–1915.
54. Borras-Basco J, Castera DE, Cortes X, et al. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refraktory uveitis in adults. Int J Clin Pharmacol Ther 2015; 53 (5): 377–390.
55. Calvo-Rio V, Blanco R, Santo-Gomez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum 2016; 46 (1): 95–101.
56. Calvo-Rio V, Santos-Gomez M, Calvo I, et al. Anti-interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: A multicenter study of twenty-five patients. Arthritis Rheumatol 2017; 69 (3): 668–675.
57. Tappeiner C, Mesquida M, Adan A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2016; 43 (12): 2183–2188.
58. Tappeiner C, Miserocchi E, Bodaghi B, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015; 42: 706–711.
59. Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophtalmol 2016; 100: 782–786.
60. Lerman MA, Lewen MD, Kempen JH, Mills MD. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 2015; 160 (1): 193–200.
61. Angeles-Han S, Yeh S. Prevention and management of cataracts in children with juvenile idiopathic arthritis-associated uveitis. Curr Rheumatol Rep 2012; 14 (2): 142–149.
62. Quiñones K, Cervantes-Castañeda RA, Hynes AY, et al. Outcomes of cataract surgery in children with chronic uveitis. J Cataract Refract Surg 2009; 35 (4): 725–731.
63. Grajewski RS, Zurek-Imhoff B, Roesel M, et al. Favourable outcome after cataract surgery with IOL implantation in uveitis associated with juvenile idiopathic arthritis. Acta Ophthalmol 2012; 90 (7): 657–662.
64. Freedman SF, Rodriguez-Rosa RE, Rojas MC, Enyedi LB. Goniotomy for glaucoma secondary to chronic childhood uveitis. Am J Ophthalmol 2002; 133 (5): 617–621.
65. Kafkala C, Hynes A, Choi J, et al. Ahmed valve implantation for uncontrolled pediatric uveitic glaucoma. J AAPOS 2005; 9 (4): 336–340.
66. Bohnsack BL, Freedman SF. Surgical outcomes in childhood uveitic glaucoma. Am J Ophthalmol 2013; 155 (1): 134–142.
67. Zannin ME, Buscain I, Vittadello F, et al. Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. Acta Ophthalmol 2012; 90: 91–95.
68. Gregory AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the systemic immunosuppressive therapy for eye diseases study. Ophthalmology 2013; 120 (1): 186–192.
69. Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol 2006; 244 (3): 281–290.
70. Haasnoot AJ, Vernie LA, Rothova A, et al. Impact of juvenile idiopathic arthritis associated uveitis in early adulthood. PLoS ONE 2016; 11 (10): e0164312
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2018 Issue 4
Most read in this issue
- Juvenile idiopatic arthritis associated uveitis
- Management of autoinflammatory diseases: Czech-Slovak adaptation of the SHARE European recommendations*
- Key note lecture